{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:00:58Z","timestamp":1787032858049,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,26]]},"DOI":"10.7759\/cureus.83026","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T05:37:28Z","timestamp":1745645848000},"source":"Crossref","is-referenced-by-count":1,"title":["Pulmonary Coccidioidomycosis Occurring in a Patient Treated With Acalabrutinib for Chronic Lymphocytic Leukemia"],"prefix":"10.7759","author":[{"given":"Zahra","family":"Gafarzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Gaultier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Salmasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruba","family":"Alchaikh Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Dasanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia P","year":"2020","unstructured":"Ghia P, Pluta A, Wach M, et al.. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020, 38:2849-61. 10.1200\/JCO.19.03355","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman JP","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, et al.. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020, 395:1278-91. 10.1016\/S0140-6736(20)30262-2","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12281-019-00350-w","article-title":"Small-molecule protein kinases inhibitors and the risk of fungal infections","volume":"13","author":"Bechman K","year":"2019","unstructured":"Bechman K, Galloway JB, Winthrop KL. Small-molecule protein kinases inhibitors and the risk of fungal infections. Curr Fungal Infect Rep. 2019, 13:229-43. 10.1007\/s12281-019-00350-w","journal-title":"Curr Fungal Infect Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez D","year":"2018","unstructured":"Ghez D, Calleja A, Protin C, et al.. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018, 131:1955-9. 10.1182\/blood-2017-11-818286","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13001","article-title":"Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: an observational study","volume":"62","author":"Ruchlemer R","year":"2019","unstructured":"Ruchlemer R, Ben-Ami R, Bar-Meir M, et al.. Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: an observational study. Mycoses. 2019, 62:1140-7. 10.1111\/myc.13001","journal-title":"Mycoses"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12281-019-00343-9","article-title":"Fungal infections with ibrutinib and other small-molecule kinase inhibitors","volume":"13","author":"Zarakas MA","year":"2019","unstructured":"Zarakas MA, Desai JV, Chamilos G, Lionakis MS. Fungal infections with ibrutinib and other small-molecule kinase inhibitors. Curr Fungal Infect Rep. 2019, 13:86-98. 10.1007\/s12281-019-00343-9","journal-title":"Curr Fungal Infect Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton's tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks RW","year":"2014","unstructured":"Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014, 14:219-32. 10.1038\/nrc3702","journal-title":"Nat Rev Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.14.9587","article-title":"Rational design and synthesis of a novel anti-leukemic agent targeting Bruton\u2032s tyrosine kinase (BTK), LFM-A13 [\u03b1-cyano-\u03b2-hydroxy-\u03b2-methyl-N-(2,5-dibromophenyl)propenamide]","volume":"274","author":"Mahajan S","year":"1999","unstructured":"Mahajan S, Ghosh S, Sudbeck EA, Zheng Y, Downs S, Hupke M, Uckun FM. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton\u2032s tyrosine kinase (BTK), LFM-A13 [\u03b1-cyano-\u03b2-hydroxy-\u03b2-methyl-N-(2,5-dibromophenyl)propenamide]. J Biol Chem. 1999, 274:9587-99. 10.1074\/jbc.274.14.9587","journal-title":"J Biol Chem"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour JF","year":"2023","unstructured":"Seymour JF, Byrd JC, Ghia P, et al.. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023, 142:687-99. 10.1182\/blood.2022018818","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-823393","article-title":"Ibrutinib blocks Btk-dependent NF-\u0138B and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis","volume":"132","author":"Bercusson A","year":"2018","unstructured":"Bercusson A, Colley T, Shah A, Warris A, Armstrong-James D. Ibrutinib blocks Btk-dependent NF-\u0138B and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis. Blood. 2018, 132:1985-8. 10.1182\/blood-2017-12-823393","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.219220","article-title":"Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus","volume":"105","author":"Blez D","year":"2020","unstructured":"Blez D, Blaize M, Soussain C, et al.. Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus. Haematologica. 2020, 105:478-89. 10.3324\/haematol.2019.219220","journal-title":"Haematologica"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated phase 2 results","volume":"135","author":"Byrd JC","year":"2020","unstructured":"Byrd JC, Wierda WG, Schuh A, et al.. Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020, 135:1204-13. 10.1182\/blood.2018884940","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01252-y","article-title":"Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies","volume":"35","author":"Furman RR","year":"2021","unstructured":"Furman RR, Byrd JC, Owen RG, et al.. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia. 2021, 35:3201-11. 10.1038\/s41375-021-01252-y","journal-title":"Leukemia"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/IPC.0000000000000722","article-title":"Disseminated cryptococcal infection in a patient receiving acalabrutinib for chronic lymphocytic leukemia","volume":"27","author":"Wilson PA","year":"2019","unstructured":"Wilson PA, Melville K. Disseminated cryptococcal infection in a patient receiving acalabrutinib for chronic lymphocytic leukemia. Infect Dis Clin Pract. 2019, 27:160-2. 10.1097\/IPC.0000000000000722","journal-title":"Infect Dis Clin Pract"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28010081","article-title":"Cerebral invasive aspergillosis in a case of chronic lymphocytic leukemia with Bruton tyrosine kinase inhibitor","volume":"28","author":"Alkharabsheh O","year":"2021","unstructured":"Alkharabsheh O, Alsayed A, Morlote DM, Mehta A. Cerebral invasive aspergillosis in a case of chronic lymphocytic leukemia with Bruton tyrosine kinase inhibitor. Curr Oncol. 2021, 28:837-41. 10.3390\/curroncol28010081","journal-title":"Curr Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00112-19","article-title":"Early events in coccidioidomycosis","volume":"33","author":"Donovan FM","year":"2019","unstructured":"Donovan FM, Shubitz L, Powell D, Orbach M, Frelinger J, Galgiani JN. Early events in coccidioidomycosis. Clin Microbiol Rev. 2019, 33:e00112-9. 10.1128\/CMR.00112-19","journal-title":"Clin Microbiol Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.10.7011-7013.2005","article-title":"Role of B cells in vaccine-induced immunity against coccidioidomycosis","volume":"73","author":"Magee DM","year":"2005","unstructured":"Magee DM, Friedberg RL, Woitaske MD, Johnston SA, Cox RA. Role of B cells in vaccine-induced immunity against coccidioidomycosis. Infect Immun. 2005, 73:7011-3. 10.1128\/IAI.73.10.7011-7013.2005","journal-title":"Infect Immun"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2018.063","article-title":"Invasive fungal infections in patients with chronic lymphoproliferative disorders in the era of target drugs","volume":"10","author":"Facchinelli D","year":"2018","unstructured":"Facchinelli D, Marchesini G, Nadali G, Pagano L. Invasive fungal infections in patients with chronic lymphoproliferative disorders in the era of target drugs. Mediterr J Hematol Infect Dis. 2018, 10:e2018063. 10.4084\/MJHID.2018.063","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.9.1481","article-title":"Intrinsic and treatment-related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practice","volume":"9","author":"Dasanu CA","year":"2008","unstructured":"Dasanu CA. Intrinsic and treatment-related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practice. Expert Opin Pharmacother. 2008, 9:1481-94. 10.1517\/14656566.9.9.1481","journal-title":"Expert Opin Pharmacother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/320081-pulmonary-coccidioidomycosis-occurring-in-a-patient-treated-with-acalabrutinib-for-chronic-lymphocytic-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T05:37:29Z","timestamp":1745645849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/320081-pulmonary-coccidioidomycosis-occurring-in-a-patient-treated-with-acalabrutinib-for-chronic-lymphocytic-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.83026","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,26]]}}}